Windtree Therapeutics
Windtree Therapeutics
WINT
NASDAQ
2.05
USD
2.50%
About
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi) inhibitors that are being developed for potential in rare and broad oncology applications.
Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm.
It also has a licensing business model with partnership out-licenses in place..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 35.5K |
| Three Month Average Volume | 19.5M |
| High Low | |
| Fifty-Two Week High | 27 USD |
| Fifty-Two Week Low | 2.81 USD |
| Fifty-Two Week High Date | 12 Oct 2023 |
| Fifty-Two Week Low Date | 25 Jul 2024 |
| Price and Volume | |
| Current Price | 8.11 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -8.83% |
| Thirteen Week Relative Price Change | 112.21% |
| Twenty-Six Week Relative Price Change | 5.20% |
| Fifty-Two Week Relative Price Change | -67.35% |
| Year-to-Date Relative Price Change | -47.08% |
| Price Change | |
| One Day Price Change | -9.28% |
| Thirteen Week Price Change | 127.13% |
| Twenty-Six Week Price Change | 15.68% |
| Five Day Price Change | -23.85% |
| Fifty-Two Week Price Change | -59.09% |
| Year-to-Date Price Change | -37.34% |
| Month-to-Date Price Change | -11.07% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.56549 USD |
| Book Value Per Share (Most Recent Quarter) | 17.65133 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -3.64524 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -25.00718 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -8.76497 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -5.23504 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.74632 USD |
| Normalized (Last Fiscal Year) | -4.44608 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -5.23504 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.74632 USD |
| Including Extraordinary Items (Last Fiscal Year) | -5.23504 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.74632 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.72024 USD |
| Cash Per Share (Most Recent Quarter) | 3.04607 USD |
| Cash Flow Per Share (Last Fiscal Year) | -5.20924 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.89658 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -4.38128 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -54,202 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -100,267.70% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,097.98% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -94,533.34% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -84.19% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -7.89% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -1,176.66% |
| EPS Change (Trailing Twelve Months) | 99.79% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 205.0K |
| Net Debt (Last Fiscal Year) | 10.9M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 0 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 0 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 14 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 442 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -13,452,000 |
| Free Cash Flow (Trailing Twelve Months) | -12,709,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 449 |
| Total Debt to Equity (Most Recent Quarter) | 19 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -57.68% |
| Return on Assets (Trailing Twelve Months) | -32.86% |
| Return on Assets (5 Year) | -44.51% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -302.78% |
| Return on Equity (Trailing Twelve Months) | -150.80% |
| Return on Equity (5 Year) | -80.63% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -63.50% |
| Return on Investment (Trailing Twelve Months) | -40.15% |
| Return on Investment (5 Year) | -48.38% |